NextCell Pharma AB (STO:NXTCL)

Sweden · Delayed Price · Currency is SEK

1.266

-0.030 (-2.31%)

At close: Mar 27, 2026

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	Aug '20 Aug 31, 2020	Aug '19 Aug 31, 2019	Aug '18 Aug 31, 2018	Aug '17 Aug 31, 2017
Stem Cell Banking		10.53M	-	-	-	-
Other		403.00K	-	-	-	-
Biotechnology		-	11.28M	13.96M	6.23M	4.46M
Biotechnology Growth		-	-19.18%	124.03%	39.82%	6.94%
Total		10.94M	11.28M	13.96M	6.23M	4.46M
Total Growth		-3.03%	-19.18%	124.03%	39.82%	6.94%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	Aug '20 Aug 31, 2020	Aug '19 Aug 31, 2019	Aug '18 Aug 31, 2018	Aug '17 Aug 31, 2017
Sweden		4.85M	11.28M	13.96M	6.23M	4.46M
Sweden Growth		-57.01%	-19.18%	124.03%	39.82%	6.94%
Denmark		5.69M	-	-	-	-
Rest of Europe		403.00K	-	-	-	-
Total		10.94M	11.28M	13.96M	6.23M	4.46M
Total Growth		-3.03%	-19.18%	124.03%	39.82%	6.94%

Source: S&P Global Market Intelligence.